FOLH1 and nonpapillary renal cell carcinoma: This rationale brought about several researchers to assess the diagnostic performance of PSMA-targeted PET/CT and evaluate the correlation between PSMA-targeting radiopharmaceuticals uptake and tumor histopathologic characteristics in newly diagnosed as well as previously treated ccRCC patients through the past six years [29,30,31,32,33,34,35,36,37,38,39,40,41,42].